Company Performance Metrics
- Charles Garner: Chief Financial Officer
Andrew Mazar: FounderPast Role: Abbott, Team Member
Lung Therapeutics is a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. Current efforts are focused on a severe complication of pneumonia, called loculated pleural effusion, a debilitating condition where fluid has built up in the chest cavity surrounding the lungs and
fibrinous scar tissue in the pleural cavity blocks fluid drainage.
Their first product, LTI-01 (single chain urokinase plasminogen activator, or scuPA), is being studied for safe clearance of fibrinous scar tissue in patients with loculated pleural effusion. By clearing the fibrinous buildup pharmaceutically, the clinical pathway for these patients is significantly improved, enabling simple draining of pleural fluid without surgery.
Their longer-term efforts will target improvement of clinical pathways for Acute Lung Injury, Idiopathic Pulmonary Fibrosis and other disease conditions.
